China BCI market grows to $530M in 2025 — 10 invasive BCI trial programs active, NeuroXess leads
Summary
China's BCI market grew to more than $530M in 2025, up from $460M in 2024, driven by rapid expansion of both invasive and non-invasive BCI clinical programs. There are now 10 active invasive BCI trial programs across Chinese hospitals. NeuroXess, NeuCyber NeuroTech, Neuracle, and BrainCo lead the domestic ecosystem. Provinces including Sichuan, Hubei, and Zhejiang have set medical service pricing for BCI to speed inclusion in the national insurance system.
Why it matters
A $530M and rapidly growing Chinese BCI market with 10 active invasive trial programs means China is not years behind the US — it is operating at comparable clinical scale with dramatically faster regulatory iteration. Province-level insurance pricing decisions for BCI — unprecedented elsewhere — give Chinese companies a reimbursement pathway that US companies are still years from achieving.
Want the full NeurotechMag Pro intelligence database?
Access 800+ papers, trials, patents, funding rounds and news items — updated daily.
Start free trial